EUVIMEDEUVIMED entdecken
Open Access

Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects

Catena Kresbach iD, Lea Holst, Melanie Schoof, Tara Leven, Carolin Göbel, Sina Neyazi iD, Jacqueline Tischendorf, Carolin Loose, Antonina Wrzeszcz, Timur Yorgan, Stefan Rutkowski, Ulrich Schüller iD

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Catena Kresbach und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms, Pyridines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mildred Scheel Cancer Career Center Hamburg/Deutsche Krebshilfe, Fördergemeinschaft Kinderkrebszentrum Hamburg, Gesellschaft für Kinderkrebsforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medulloblastoma (MB) is the most common malignant brain tumor in children and requires intensive multimodal therapy. Long-term survival is still dissatisfying and, most importantly, survivors frequently suffer from severe treatment-associated morbidities. The sonic hedgehog pathway (SHH) in SHH MB provides a promising target for specific therapeutic agents. The small molecule Vismodegib allosterically inhibits SMO, the main upstream activator of SHH. Vismodegib has proven effective in the treatment of MB in mice and in clinical studies. However, due to irreversible premature epiphyseal growth plate fusions after systemic application to infant mice and children, its implementation to pediatric patients has been limited. Intraventricular Vismodegib application might provide a promising novel treatment strategy for pediatric medulloblastoma patients.

Methods

Infant medulloblastoma-bearing Math1-cre::Ptch1Fl/Fl mice were treated with intraventricular Vismodegib in order to evaluate efficacy on tumor growth and systemic side effects.

Results

We show that intraventricular Vismodegib treatment of Math1-cre::Ptch1Fl/Fl mice leads to complete or partial tumor remission only 2 days after completed treatment. Intraventricular treatment also significantly improved symptom-free survival in a dose-dependent manner. At the same time, intraventricular application prevented systemic side effects in the form of anatomical or histological bone deformities.

Conclusions

We conclude that intraventricular application of a SHH pathway inhibitor combines the advantages of a specific treatment agent with precise drug delivery and might evolve as a promising new way of targeted treatment for SHH MB patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaCerebellar NeoplasmsPyridinesHumansMiceAnimalsChildHedgehog ProteinsAnilidesDisease Models, Animal

Stichwörter der Autor:innen

Sonic Hedgehog Inhibitionintraventricular therapymedulloblastomatargeted treatment

Substanzen

HhAntag691Hedgehog ProteinsAnilidesSHH protein, humanPyridines

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.
  • Center of Diagnostics, Institute of Neuropathology, Center of Diagnostics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
  • Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Catena Kresbach, Sina Neyazi, Ulrich Schüller

Förderung

  • Mildred Scheel Cancer Career Center Hamburg/Deutsche Krebshilfe
  • Fördergemeinschaft Kinderkrebszentrum Hamburg
  • Gesellschaft für Kinderkrebsforschung
  • Hamburger Krebsgesellschaft
  • German Children's Cancer Foundation
  • Hubertus Wald Tumorzentrum, University Cancer Center Hamburg
  • German Society for Pediatric Oncology and Hematology
  • German Children’s Cancer Foundation

Zitieren

APA

Kresbach, C., Holst, L., Schoof, M., Leven, T., Göbel, C., Neyazi, S., Tischendorf, J., Loose, C., Wrzeszcz, A., Yorgan, T., Rutkowski, S., & Schüller, U. (2024). Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad191

Vancouver

Kresbach C, Holst L, Schoof M, Leven T, Göbel C, Neyazi S, et al. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad191

BibTeX
@article{Kresbach2024,
  author = {Kresbach, Catena and Holst, Lea and Schoof, Melanie and Leven, Tara and Göbel, Carolin and Neyazi, Sina and Tischendorf, Jacqueline and Loose, Carolin and Wrzeszcz, Antonina and Yorgan, Timur and Rutkowski, Stefan and Schüller, Ulrich},
  title = {Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad191}
}
Kostenlos starten →